Evidence map›Paper›PMID 31299906›Full record

Observational studyBMC cardiovascular disorders2019

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).

Raffaele De Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, Esteban López-de-Sá, Thomas W Weiss, Johannes Waltenberger, Jan Steffel, Joris R de Groot and 8 more

Registry-linked trialOpen access · goldAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cardiovascular disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02944019 (Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02944019 completednot on this map

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

TypeobservationalSponsorDaiichi SankyoRan2015 to 2022Enrolled13,980ConditionsAtrial FibrillationArmsEdoxaban
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. An Updated Pooled Analysis of Off-Label Under and Over-Dosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022
    Observational
  17. Article
  18. Article
  19. Observational
  20. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 11 countries.

Raffaele De CaterinaUniversità degli Studi di Pisa, Pisa, Italy.
Peter KellyHRB Stroke Clinical Trials Network Ireland, University College Dublin, Dublin, Ireland.
Pedro MonteiroCentro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Jean Claude DeharoHôpital de la Timone, Marseille, France.
Carlo de AsmundisUniversitair Ziekenhuis Brussels, Dilbeek, Belgium.
Esteban López-de-SáHospital Universitario La Paz, IDIPAZ, Madrid, Spain.
Thomas W WeissKarl Landsteiner Institute for Cardiometabolics and SFU, Vienna, Austria.
Johannes WaltenbergerUniversity of Munster, Münster, Germany.
Jan SteffelUniversity Hospital of Zurich, Zürich, Switzerland.
Joris R de GrootAmsterdam University Medical Centers/University of Amsterdam, Amsterdam, The Netherlands.
Pierre LevyUniversité Paris-Dauphine, PSL Research University, Paris, France.
Ameet BakhaiRoyal Free London NHS Foundation Trust, Chase Farm Hospital, London, UK.
Wolfgang ZierhutDaiichi Sankyo Europe GmbH, Munich, Germany.
Petra LaeisDaiichi Sankyo Europe GmbH, Munich, Germany.
Michael KerschnitzkiDaiichi Sankyo Europe GmbH, Munich, Germany.
Paul-Egbert ReimitzDaiichi Sankyo Europe GmbH, Munich, Germany.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, IBR 136, Wolfson Drive, Birmingham, B15 2TT, UK. p.kirchhof@bham.ac.uk.ORCID 0000-0002-1881-0197
ETNA-AF-Europe investigators
Daiichi Sankyo (Germany) · DEHospital Universitario La Paz · ESRoyal Free London NHS Foundation Trust · GBUniversity College Dublin · IEUniversity of Münster · DEAtrial Fibrillation NETwork · DEFondazione Stella Maris · ITHospitais da Universidade de Coimbra · PTUniversitair Ziekenhuis Brussel · BEUniversité Paris Sciences et Lettres · FRUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have substantially improved anticoagulation therapy for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). The available routine care data have demonstrated the safety of different NOACs; however, such data for edoxaban are scarce. Here, we report baseline characteristics of 13,638 edoxaban-treated patients with AF enrolled between November 2016 and February 2018.

methodsETNA-AF-Europe is a multinational, multi-centre, post-authorisation, observational study conducted in 825 sites in 10 European countries. Patients will be followed up for four years.

resultsOverall, 13,980 patients were enrolled of which 342 patients were excluded from the analysis. Mean patient age was 73.6 years with an average creatinine clearance of 69.4 mL/min. 56.6% were male. The calculated CHA

conclusionEdoxaban was predominantly initiated in older, often anticoagulation-naïve, unselected European patients with AF, with a good overall adherence to the approved label.

trial registrationNCT02944019; Date of registration: October 24, 2016.

Indexed as

Practice Patterns, Physicians'Administration, OralAgedAged, 80 and overAtrial FibrillationDrug LabelingDrug UtilizationEuropeFactor Xa InhibitorsFemaleGuideline AdherenceHemorrhageHumansMaleMiddle AgedPractice Guidelines as TopicedoxabanFactor Xa InhibitorsPyridinesThiazolesMajor bleedingNon-vitamin K antagonist oral anticoagulantsReal-worldRegistrySafety outcomesStroke prevention

Identifiers

PMID31299906
PMCPMC6625115
OpenAlexW2959217544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.